A Phase 2 interventional study of Sotatercept and Placebo in Anemia, sponsored by Celgene. Completed at 24 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-01.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Anemia by Bristol-Myers Squibb — 1 open to participants now, 8 under way, 5 of them phase 3. Anemia · Bristol-Myers Squibb.
Among the 16 studies in Anemia by Bristol-Myers Squibb, this one is the 12th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2010, is one of 6 in phase 2, and was the 3rd registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →1 of the 16 studies in Anemia by Bristol-Myers Squibb is open now, in 1 country. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Germany
Ages 18+
By country, each count listing its studies:
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 8 · Phase 4 1
First in 2005; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 189 across the 15 interventional studies, 190 across the 1 observational. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
1 of the studies in Anemia by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05664737Bristol-Myers SquibbA Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia | 2027-07-16 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Anemia by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is the first study in hemodialysis subjects with anemia to evaluate the pharmacokinetics, safety, efficacy, tolerability, and pharmacodynamics of sotatercept (ACE-011)
Part 1:
Approximately 8 subjects will be randomized to receive either a single 0.1 mg/kg subcutaneous dose of sotatercept or matching placebo in a 3:1 ratio
Part 2:
Approximately 8 subjects will be randomized to each of the 3 sequential dose groups (0.3mg/kg or 0.5mg/kg or 0.7 mg/kg) with a 3:1 ratio of sotatercept or placebo (6 subjects in the sotatercept arm and 2 in the placebo arm). A total of 24-36 subjects may be randomized in the 3 dose groups.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Approximately 8 subjects will be randomized to receive either a single 0.1 mg/kg subcutaneous dose of sotatercept or matching placebo in a 3:1 ratio
Biological: Sotatercept
Dose Group 1: 0.3 mg/kg sotatercept subcutaneous every 28 days
Biological: Sotatercept
Dose Group 2: 0.5 mg/kg sotatercept subcutaneous every 28 days
Biological: Sotatercept
Dose Group 3: 0.7 mg/kg sotatercept subcutaneous every 28 days
Biological: Sotatercept
The Placebo to Sotatercept ratio is 1:3 meaning for every 1 patient that receives Placebo, 3 patients will receive Sotatercept.
Biological: Placebo
Part 1: Sotatercept single dose 0.1mg/kg subcutaneous Part 2: Sotatercept starting dose groups of 0.3mg/kg, 0.5mg/kg or 0.7 mg/kg in a sequential design, dosed subcutaneously every 28 days for up to 8 doses
Also known as: ACE-011
Placebo
Observed Maximum Concentration (Cmax)
Cmax is a pharmacokinetic parameter defined as the observed maximum concentration of the study drug in the serum and/or blood. Cmax will be estimated from the sotatercept concentration versus time data using noncompartmental method.
Time frame: From first dose up to Day 28
Time to Maximum Concentration (Tmax)
Time to observed maximum concentration (Tmax) is defined as the amount of time in days for a drug to reach the maximum concentration after administration.
Time frame: From first dose up to Day 28
Area Under Curve (AUC)-28 Days
AUC-28 days is defined as area under the concentration-time curve over the first 28-day dosing interval
Time frame: From first dose up to Day 28
AUCinf: Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity
Area under the concentration-time curve from time zero extrapolated to infinity. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint.
Time frame: From first dose up to Day 28
Apparent Total Clearance (CL/F)
Apparent Total Clearance (CL/F) is defined as the volume of plasma from which the study drug is completely removed per unit of time. It is equal to the drug dose divided by the area-under-the-curve.
Time frame: From first dose up to Day 28
Apparent Volume of Distribution Based on Terminal Phase (Vz/F)
Apparent volume of distribution based on terminal phase (Vz/F) is defined as the apparent volume in which the current amount of drug in the body must be dispersed in order to give the current plasma concentration. Apparent volume of distribution is important for determining the dose required to produce a desired plasma concentration of the drug.
Time frame: From first dose up to Day 28
Terminal Half-Life (t1/2,z)
Terminal plasma half-life (t1/2,z) is the time taken for concentration of the study drug to decrease from its maximum concentration (Cmax) to half of Cmax in the blood plasma.
Time frame: Days 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 15, 22, 29, 43, 57, 85 and 113
The Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
Time frame: From first dose up to 115 days post last dose
Number of Participants With Hemoglobin > 12g/dL
Number of participants with hemoglobin \> 12g/dL including Hb values obtained after first study drug dose and before any rescue.
Time frame: Pre-dose; Dose 1-Days 1, 8, 15, 22, 29; Doses 2, 3, 4, 5, 6, 7-Days 1, 15, 29; Follow-up Phase Days 225, 253, 281, and 309
Proportion of Participants With Rise in Hemoglobin > 2 g/dL During 4 Week Period
Proportion of participants with rise in hemoglobin (Hb) \> 2 g/dL during a 4-week period including Hb values obtained after first study drug dose and before any rescue.
Time frame: Pre-dose; Dose 1-Days 1, 8, 15, 22, 29; Doses 2, 3, 4, 5, 6, 7-Days 1, 15, 29; Follow-up Phase Days 225, 253, 281, and 309
Blood Pressure Changes From Baseline
Blood pressure was generally recorded on the day of dialysis and represent pre-dialysis values. Baseline is defined as blood pressure measurements recorded on Day 1 of the first dose administered.
Time frame: From pre-dose up to the final visit 112 days after last dose (up to 225 days)
Changes in Follicle Stimulating Hormone (FSH)
The change in follicle stimulating measured at pre-specified timepoints throughout the treatment period.
Time frame: Day 1 (baseline), Day 15, Day 29, and Day 113
Number of Participants With Hemoglobin > 10g/dL
Number of participants with hemoglobin \> 10g/dL including Hb values obtained after first study drug dose and before any rescue. Baseline is defined as hemoglobin measurements recorded on Day 1 of the first dose administered.
Time frame: Pre-dose; Dose 1-Days 1, 8, 15, 22, 29; Doses 2, 3, 4, 5, 6, 7-Days 1, 15, 29; Follow-up Phase Days 225, 253, 281, and 309
Number of Participants With Change From Baseline Hemoglobin ≥ 1g/dL
Number of participants with a change from in hemoglobin values ≥ 1g/dL including Hb values obtained after first study drug dose and before any rescue. Baseline is defined as hemoglobin measurements recorded on Day 1 of the first dose administered.
Time frame: Pre-dose; Dose 1-Days 1, 8, 15, 22, 29; Doses 2, 3, 4, 5, 6, 7-Days 1, 15, 29; Follow-up Phase Days 225, 253, 281, and 309
Number of Participants With Hemoglobin > 10g/dL and Change From Baseline Hemoglobin ≥ 1g/dL
Number of participants with Hemoglobin \> 10g/dL and a change from in hemoglobin values ≥ 1g/dL including Hb values obtained after first study drug dose and before any rescue. Baseline is defined as hemoglobin measurements recorded on Day 1 of the first dose administered.
Time frame: Pre-dose; Dose 1-Days 1, 8, 15, 22, 29; Doses 2, 3, 4, 5, 6, 7-Days 1, 15, 29; Follow-up Phase Days 225, 253, 281, and 309
Length of Time to Rescue Therapy
The length of time in days that participants who were rescued received treatment. When applicable, participants were rescued for anemia. During the rescue, participants discontinued sotatercept and were unblinded to the study treatment. Participants who were rescued continued in the treatment phase of 200 days and a follow-up phase of 112 days after the treatment phase. Rescue is defined as the need for a blood transfusion or Erythropoiesis-stimulating agent (ESA) therapy.
Time frame: From first dose up to blood transfusion or ESA therapy, up to approximately 209 days
Change From Baseline in Hemoglobin Values
Dose Cycle 1 is defined as the first 28 days of treatment for Dose Groups 0.3 mg/kg, 0.5 mg/kg, and 0.7 mg/kg and the first 14 days of treatment for Dose Group 0.7/0.4 mg/kg. End of the Treatment Period is defined as the day before the follow-up phase started. Baseline is defined as hemoglobin measurements recorded on Day 1 of the first dose administered.
Time frame: From first dose up to Day 225
| Milestone | Part 1-Placebo | Part 1-ACE-011 0.1 mg/kg | Part 2- Placebo | Part 2-0.3 mg/kg | Part 2-0.5 mg/kg | Part 2-0.7 mg/kg | Part 2-0.7/0.4 mg/kg |
|---|---|---|---|---|---|---|---|
| Started | 1 | 6 | 11 | 9 | 8 | 9 | 6 |
| Completed | 1 | 5 | 5 | 7 | 6 | 8 | 5 |
| Not completed | 0 | 1 | 6 | 2 | 2 | 1 | 1 |
| Withdrew: Death | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Other reasons | 0 | 0 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Kidney transplant | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrew consent | 0 | 0 | 1 | 1 | 2 | 1 | 1 |
Cmax is a pharmacokinetic parameter defined as the observed maximum concentration of the study drug in the serum and/or blood. Cmax will be estimated from the sotatercept concentration versus time data using noncompartmental method.
| ug/mL | Part 1-Placebo | Part 1-ACE-011 0.1 mg/kg | Part 2- Placebo | Part 2-0.3 mg/kg | Part 2-0.5 mg/kg | Part 2-0.7 mg/kg | Part 2-0.7/0.4 mg/kg |
|---|---|---|---|---|---|---|---|
| Observed Maximum Concentration (Cmax) | — | 1.022 ± 0.576 | — | 2.40 ± 0.96 | 3.66 ± 0.67 | 3.97 ± 1.64 | 7.71 ± 1.97 |
Time to observed maximum concentration (Tmax) is defined as the amount of time in days for a drug to reach the maximum concentration after administration.
| Days | Part 1-Placebo | Part 1-ACE-011 0.1 mg/kg | Part 2- Placebo | Part 2-0.3 mg/kg | Part 2-0.5 mg/kg | Part 2-0.7 mg/kg | Part 2-0.7/0.4 mg/kg |
|---|---|---|---|---|---|---|---|
| Time to Maximum Concentration (Tmax) | — | 6 (3 to 14) | — | 7 (3 to 14) | 8 (4 to 12) | 7 (4 to 10) | 5 (3 to 13) |
AUC-28 days is defined as area under the concentration-time curve over the first 28-day dosing interval
| ug·day/mL | Part 1-Placebo | Part 1-ACE-011 0.1 mg/kg | Part 2- Placebo | Part 2-0.3 mg/kg | Part 2-0.5 mg/kg | Part 2-0.7 mg/kg | Part 2-0.7/0.4 mg/kg |
|---|---|---|---|---|---|---|---|
| Area Under Curve (AUC)-28 Days | — | 20.6 ± 11.4 | — | 50.64 ± 17.67 | 78.03 ± 13.34 | 87.51 ± 36.68 | 126.96 ± 20.75 |
Area under the concentration-time curve from time zero extrapolated to infinity. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint.
| ug·day/mL | Part 1-Placebo | Part 1-ACE-011 0.1 mg/kg | Part 2- Placebo | Part 2-0.3 mg/kg | Part 2-0.5 mg/kg | Part 2-0.7 mg/kg | Part 2-0.7/0.4 mg/kg |
|---|---|---|---|---|---|---|---|
| AUCinf: Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity | — | 35.8 ± 17.4 | — | — | — | — | — |
Apparent Total Clearance (CL/F) is defined as the volume of plasma from which the study drug is completely removed per unit of time. It is equal to the drug dose divided by the area-under-the-curve.
| L/day | Part 1-Placebo | Part 1-ACE-011 0.1 mg/kg | Part 2-Placebo | Part 2-0.3 mg/kg | Part 2-0.5 mg/kg | Part 2-0.7 mg/kg | Part 2-0.7/0.4 mg/kg |
|---|---|---|---|---|---|---|---|
| Apparent Total Clearance (CL/F) | — | 3.22 ± 1.20 | — | 0.255 ± 0.068 | 0.261 ± 0.075 | 0.532 ± 0.654 | 0.298 ± 0.112 |
Apparent volume of distribution based on terminal phase (Vz/F) is defined as the apparent volume in which the current amount of drug in the body must be dispersed in order to give the current plasma concentration. Apparent volume of distribution is important for determining the dose required to produce a desired plasma concentration of the drug.
| mL/kg | Part 1-Placebo | Part 1-ACE-011 0.1 mg/kg | Part 2- Placebo | Part 2-0.3 mg/kg | Part 2-0.5 mg/kg | Part 2-0.7 mg/kg | Part 2-0.7/0.4 mg/kg |
|---|---|---|---|---|---|---|---|
| Apparent Volume of Distribution Based on Terminal Phase (Vz/F) | — | 98 ± 38 | — | — | — | — | — |
Terminal plasma half-life (t1/2,z) is the time taken for concentration of the study drug to decrease from its maximum concentration (Cmax) to half of Cmax in the blood plasma.
| Day | Part 1-Placebo | Part 1-ACE-011 0.1 mg/kg | Part 2- Placebo | Part 2-0.3 mg/kg | Part 2-0.5 mg/kg | Part 2-0.7 mg/kg | Part 2-0.7/0.4 mg/kg |
|---|---|---|---|---|---|---|---|
| Terminal Half-Life (t1/2,z) | — | 21.1 ± 3.9 | — | 24.3 ± 3.28 | 32.1 ± 19.9 | 22.2 ± 7.00 | 19.6 ± 2.91 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
| Participants | Part 1-Placebo | Part 1-ACE-011 0.1 mg/kg | Part 2- Placebo | Part 2-0.3 mg/kg | Part 2-0.5 mg/kg | Part 2-0.7 mg/kg | Part 2-0.7/0.4 mg/kg |
|---|---|---|---|---|---|---|---|
| The Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) | 1 | 6 | 7 | 8 | 6 | 8 | 4 |
Number of participants with hemoglobin \> 12g/dL including Hb values obtained after first study drug dose and before any rescue.
| Participants | Part 1-Placebo | Part 1-ACE-011 0.1 mg/kg | Part 2- Placebo | Part 2-0.3 mg/kg | Part 2-0.5 mg/kg | Part 2-0.7 mg/kg | Part 2-0.7/0.4 mg/kg |
|---|---|---|---|---|---|---|---|
| Number of Participants With Hemoglobin > 12g/dL | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Proportion of participants with rise in hemoglobin (Hb) \> 2 g/dL during a 4-week period including Hb values obtained after first study drug dose and before any rescue.
| Participants | Part 1-Placebo | Part 1-ACE-011 0.1 mg/kg | Part 2- Placebo | Part 2-0.3 mg/kg | Part 2-0.5 mg/kg | Part 2-0.7 mg/kg | Part 2-0.7/0.4 mg/kg |
|---|---|---|---|---|---|---|---|
| Proportion of Participants With Rise in Hemoglobin > 2 g/dL During 4 Week Period | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
Blood pressure was generally recorded on the day of dialysis and represent pre-dialysis values. Baseline is defined as blood pressure measurements recorded on Day 1 of the first dose administered.
| mmHg | Part 1-Placebo | Part 1-ACE-011 0.1 mg/kg | Part 2- Placebo | Part 2-0.3 mg/kg | Part 2-0.5 mg/kg | Part 2-0.7 mg/kg | Part 2-0.7/0.4 mg/kg |
|---|---|---|---|---|---|---|---|
| Systolic Blood Pressure Baseline Day 1 | 151.0 ± NA | 142.8 ± 13.11 | 129.4 ± 27.99 | 145.9 ± 9.75 | 141.4 ± 18.72 | 139.9 ± 29.25 | 135.0 ± 25.09 |
| Systolic Blood Pressure Final Visit | 163.0 ± NA | 134.6 ± 6.95 | 145.0 ± 26.91 | 167.0 ± 12.81 | 154.0 ± 34.47 | 154.3 ± 22.93 | 131.8 ± 12.79 |
| Diastolic Blood Pressure Baseline Day 1 | 75.0 ± NA | 81.5 ± 7.56 | 71.6 ± 13.42 | 78.2 ± 12.45 | 74.3 ± 8.41 | 64.6 ± 13.33 | 72.0 ± 16.10 |
| Diastolic Blood Pressure Final Visit | 83.0 ± NA | 86.2 ± 15.93 | 79.7 ± 15.53 | 85.2 ± 9.83 | 83.6 ± 18.98 | 75.3 ± 9.19 | 71.6 ± 10.01 |
The change in follicle stimulating measured at pre-specified timepoints throughout the treatment period.
| IU/L | Part 1-Placebo | Part 1-ACE-011 0.1 mg/kg |
|---|---|---|
| Day 1 (baseline) | 23.5 ± NA | 36.9 ± 67.65 |
| Day 15 | 17.1 ± NA | 51.8 ± 80.76 |
| Day 29 | 17.5 ± NA | 37.4 ± 67.69 |
| Day 113 | 11.8 ± NA | 48.2 ± 78.81 |
Number of participants with hemoglobin \> 10g/dL including Hb values obtained after first study drug dose and before any rescue. Baseline is defined as hemoglobin measurements recorded on Day 1 of the first dose administered.
| Participants | Part 2- Placebo | Part 2-0.3 mg/kg | Part 2-0.5 mg/kg | Part 2-0.7 mg/kg | Part 2-0.7/0.4 mg/kg |
|---|---|---|---|---|---|
| Number of Participants With Hemoglobin > 10g/dL | 3 | 3 | 5 | 7 | 2 |
Number of participants with a change from in hemoglobin values ≥ 1g/dL including Hb values obtained after first study drug dose and before any rescue. Baseline is defined as hemoglobin measurements recorded on Day 1 of the first dose administered.
| Participants | Part 2- Placebo | Part 2-0.3 mg/kg | Part 2-0.5 mg/kg | Part 2-0.7 mg/kg | Part 2-0.7/0.4 mg/kg |
|---|---|---|---|---|---|
| Number of Participants With Change From Baseline Hemoglobin ≥ 1g/dL | 2 | 3 | 4 | 7 | 2 |
Number of participants with Hemoglobin \> 10g/dL and a change from in hemoglobin values ≥ 1g/dL including Hb values obtained after first study drug dose and before any rescue. Baseline is defined as hemoglobin measurements recorded on Day 1 of the first dose administered.
| Participants | Part 2- Placebo | Part 2-0.3 mg/kg | Part 2-0.5 mg/kg | Part 2-0.7 mg/kg | Part 2-0.7/0.4 mg/kg |
|---|---|---|---|---|---|
| Number of Participants With Hemoglobin > 10g/dL and Change From Baseline Hemoglobin ≥ 1g/dL | 2 | 2 | 4 | 6 | 2 |
The length of time in days that participants who were rescued received treatment. When applicable, participants were rescued for anemia. During the rescue, participants discontinued sotatercept and were unblinded to the study treatment. Participants who were rescued continued in the treatment phase of 200 days and a follow-up phase of 112 days after the treatment phase. Rescue is defined as the need for a blood transfusion or Erythropoiesis-stimulating agent (ESA) therapy.
| Days | Part 2- Placebo | Part 2-0.3 mg/kg | Part 2-0.5 mg/kg | Part 2-0.7 mg/kg | Part 2-0.7/0.4 mg/kg |
|---|---|---|---|---|---|
| Length of Time to Rescue Therapy | 44.8 ± 43.96 | 69.8 ± 59.12 | 47.4 ± 32.86 | 100.4 ± 55.73 | 117.5 ± 73.37 |
Dose Cycle 1 is defined as the first 28 days of treatment for Dose Groups 0.3 mg/kg, 0.5 mg/kg, and 0.7 mg/kg and the first 14 days of treatment for Dose Group 0.7/0.4 mg/kg. End of the Treatment Period is defined as the day before the follow-up phase started. Baseline is defined as hemoglobin measurements recorded on Day 1 of the first dose administered.
| g/L | Part 2- Placebo | Part 2-0.3 mg/kg | Part 2-0.5 mg/kg | Part 2-0.7 mg/kg | Part 2-0.7/0.4 mg/kg |
|---|---|---|---|---|---|
| End of Dose Cycle 1 | -3.3 ± 7.57 | -6.9 ± 6.94 | -2.9 ± 8.18 | 0.8 ± 5.85 | 1.0 ± 2.45 |
| Peak Value During Dose Cycle 1 | -0.9 ± 7.08 | 5.2 ± 8.24 | 7.1 ± 3.98 | 8.4 ± 3.75 | 5.4 ± 4.10 |
| End of Treatment Period | 12.5 ± 12.42 | 12.8 ± 13.75 | 15.3 ± 8.22 | 15.0 ± 12.11 | 2.8 ± 6.91 |
Collected over Participants were assessed for all-cause mortality from their randomization to study completion, (up to approximately 66 months). SAEs and Other AEs were assessed from first dose up to 115 days post last dose (up to 340 days).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1 - Placebo | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Part 1 - ACE-011 0.1 mg/kg | 1/6 (16.7%) | 2/6 (33.3%) | 6/6 (100%) |
| Part 2 - Placebo | 2/11 (18.2%) | 3/11 (27.3%) | 6/11 (54.5%) |
| Part 2 - 0.3 mg/kg | 0/9 (0%) | 4/9 (44.4%) | 8/9 (88.9%) |
| Part 2 - 0.5 mg/kg | 0/8 (0%) | 0/8 (0%) | 6/8 (75%) |
| Part 2 - 0.7 mg/kg | 0/9 (0%) | 5/9 (55.6%) | 8/9 (88.9%) |
| Part 2 - 0.7/0.4 mg/kg | 0/6 (0%) | 1/6 (16.7%) | 4/6 (66.7%) |
| Event | Part 1 - Placebo | Part 1 - ACE-011 0.1 mg/kg | Part 2 - Placebo | Part 2 - 0.3 mg/kg | Part 2 - 0.5 mg/kg | Part 2 - 0.7 mg/kg | Part 2 - 0.7/0.4 mg/kg |
|---|---|---|---|---|---|---|---|
| ANGINA PECTORISCardiac disorders | 0/1 | 1/6 | 2/11 | 1/9 | 0/8 | 0/9 | 0/6 |
| GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders | 0/1 | 0/6 | 0/11 | 0/9 | 0/8 | 0/9 | 1/6 |
| CARDIAC FAILURE CONGESTIVECardiac disorders | 0/1 | 1/6 | 0/11 | 0/9 | 0/8 | 0/9 | 0/6 |
| FLUID OVERLOADMetabolism and nutrition disorders | 0/1 | 1/6 | 0/11 | 0/9 | 0/8 | 0/9 | 0/6 |
| RENAL FAILURE CHRONICRenal and urinary disorders | 0/1 | 1/6 | 0/11 | 0/9 | 0/8 | 0/9 | 0/6 |
| ANAEMIABlood and lymphatic system disorders | 0/1 | 0/6 | 0/11 | 1/9 | 0/8 | 0/9 | 0/6 |
| ACUTE MYOCARDIAL INFARCTIONCardiac disorders | 0/1 | 0/6 | 0/11 | 0/9 | 0/8 | 1/9 | 0/6 |
| ANGINA UNSTABLECardiac disorders | 0/1 | 0/6 | 0/11 | 1/9 | 0/8 | 0/9 | 0/6 |
| ATRIAL FIBRILLATIONCardiac disorders | 0/1 | 0/6 | 1/11 | 1/9 | 0/8 | 0/9 | 0/6 |
| NAUSEAGastrointestinal disorders | 0/1 | 0/6 | 1/11 | 0/9 | 0/8 | 1/9 | 0/6 |
| Event | Part 1 - Placebo | Part 1 - ACE-011 0.1 mg/kg | Part 2 - Placebo | Part 2 - 0.3 mg/kg | Part 2 - 0.5 mg/kg | Part 2 - 0.7 mg/kg | Part 2 - 0.7/0.4 mg/kg |
|---|---|---|---|---|---|---|---|
| HYPOGLYCAEMIAMetabolism and nutrition disorders | 1/1 | 0/6 | 0/11 | 0/9 | 0/8 | 1/9 | 0/6 |
| NAUSEAGastrointestinal disorders | 0/1 | 0/6 | 1/11 | 1/9 | 1/8 | 4/9 | 0/6 |
| HYPERTENSIONVascular disorders | 0/1 | 0/6 | 1/11 | 3/9 | 0/8 | 4/9 | 0/6 |
| FATIGUEGeneral disorders | 0/1 | 1/6 | 2/11 | 2/9 | 0/8 | 1/9 | 2/6 |
| ARTERIOVENOUS FISTULA SITE COMPLICATIONInjury, poisoning and procedural complications | 0/1 | 2/6 | 1/11 | 0/9 | 1/8 | 0/9 | 0/6 |
| CONSTIPATIONGastrointestinal disorders | 0/1 | 0/6 | 1/11 | 2/9 | 0/8 | 0/9 | 0/6 |
| PAINGeneral disorders | 0/1 | 0/6 | 1/11 | 2/9 | 0/8 | 0/9 | 0/6 |
| BLOOD PHOSPHORUS INCREASEDInvestigations | 0/1 | 0/6 | 0/11 | 0/9 | 0/8 | 2/9 | 0/6 |
| DIZZINESSNervous system disorders | 0/1 | 0/6 | 0/11 | 0/9 | 0/8 | 2/9 | 0/6 |
| HYPOTENSIONVascular disorders | 0/1 | 0/6 | 2/11 | 0/9 | 0/8 | 1/9 | 0/6 |
| Age, Categorical(Participants) | Part 1-Placebo | Part 1-ACE-011 0.1 mg/kg | Part 2- Placebo | Part 2-0.3 mg/kg | Part 2-0.5 mg/kg | Part 2-0.7 mg/kg | Part 2-0.7/0.4 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 5 | 9 | 7 | 6 | 5 | 4 | 37 |
| >=65 years | 0 | 1 | 2 | 2 | 2 | 4 | 2 | 13 |
| Sex: Female, Male(Participants) | Part 1-Placebo | Part 1-ACE-011 0.1 mg/kg | Part 2- Placebo | Part 2-0.3 mg/kg | Part 2-0.5 mg/kg | Part 2-0.7 mg/kg | Part 2-0.7/0.4 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 1 | 1 | 4 | 6 | 1 | 7 | 1 | 21 |
| Male | 0 | 5 | 7 | 3 | 7 | 2 | 5 | 29 |
| Ethnicity (NIH/OMB)(Participants) | Part 1-Placebo | Part 1-ACE-011 0.1 mg/kg | Part 2- Placebo | Part 2-0.3 mg/kg | Part 2-0.5 mg/kg | Part 2-0.7 mg/kg | Part 2-0.7/0.4 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 | 2 | 4 | 2 | 1 | 11 |
| Not Hispanic or Latino | 1 | 5 | 10 | 7 | 4 | 7 | 5 | 39 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part 1-Placebo | Part 1-ACE-011 0.1 mg/kg | Part 2- Placebo | Part 2-0.3 mg/kg | Part 2-0.5 mg/kg | Part 2-0.7 mg/kg | Part 2-0.7/0.4 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Black or African American | 0 | 3 | 6 | 6 | 4 | 1 | 4 | 24 |
| White | 1 | 3 | 3 | 3 | 4 | 7 | 1 | 22 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Ran from Jun 2010 to primary completion in Mar 2016, 68 months.
Results were first posted in Mar 2024, 7 years 11 months after primary completion. A results delay was requested in Mar 2017.
Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's 68 months is above that.
Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sotatercept